Drugs / FCN-011
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04687423 | Apr 2021 → Oct 2023 | neoplasm | Fochon Pharmaceuticals, Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FCN-011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04687423 ↗ |
| Route | Oral | “FCN-011 will be given orally in ascending doses starting at 50 mg Q12h or 100mg QD until the maximum tolerated dose or recommended dose is reached.” NCT04687423 ↗ |